Skip to main content
SpringerLink
Log in

Antithrombotic Therapy in Heart Failure and Cardiomyopathy

  • Chapter
  • First Online:
Antithrombotic Drug Therapy in Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1204 Accesses

Abstract

Patients with heart failure and cardiomyopathy often present with risk factors that may warrant anti-thrombotic therapy, such as atrial fibrillation, left ventricular thrombus, and the presence of a hypercoagulable state. Decades of clinical studies have provided a wealth of information and speculations, but the current role of prophylactic antiplatelet and anticoagulant therapies remained controversial. Post hoc analyses from large heart failure trials provided evidence that warfarin use was associated with improved clinical outcomes despite the lack of a significant reduction in thromboembolic risks. However, prospective randomized trials have identified an unexpected benefit of reduced heart failure hospitalizations in those treated with warfarin, which may also be interpreted as potential risk with routine administration of aspirin therapy. Ongoing clinical trials may provide the necessary clinical evidence to guide future recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rosamond W, Flegal K, Friday G et al (2009) Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3):480–406

    Article  PubMed  Google Scholar 

  2. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ (1997) Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 79(7):909–913

    Article  PubMed  CAS  Google Scholar 

  3. Dunkman WB (1995) Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk 2(2):107–117

    Article  PubMed  CAS  Google Scholar 

  4. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL (1981) The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47(3):525–531

    Article  PubMed  CAS  Google Scholar 

  5. Spodick DH, Littmann D (1958) Idiopathic myocardial hypertrophy. Am J Cardiol 1(5):610–623

    Article  PubMed  CAS  Google Scholar 

  6. Sirajuddin RA, Miller AB, Geraci SA (2002) Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: a critical literature review. J Card Fail 8(1):48–53

    Article  PubMed  CAS  Google Scholar 

  7. Cioffi G, Pozzoli M, Forni G et al (1996) Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 17(9):1381–1389

    Article  PubMed  CAS  Google Scholar 

  8. Katz SD, Marantz PR, Biasucci L et al (1993) Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 126(1):141–146

    Article  PubMed  CAS  Google Scholar 

  9. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW (1995) Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 129(3):564–570

    Article  PubMed  CAS  Google Scholar 

  10. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN (1993) Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87(6 Suppl):VI94–VI101

    PubMed  CAS  Google Scholar 

  11. Olsson LG, Swedberg K, Ducharme A et al (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47(10):1997–2004

    Article  PubMed  Google Scholar 

  12. Freudenberger RS, Hellkamp AS, Halperin JL et al (2007) Risk of thromboembolism in heart failure: an analysis from the sudden cardiac death in heart failure trial (SCD-HeFT). Circulation 115(20):2637–2641

    Article  PubMed  Google Scholar 

  13. Loh E, Sutton MS, Wun CC et al (1997) Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 336(4):251–257

    Article  PubMed  CAS  Google Scholar 

  14. Dotsenko O, Kakkar VV (2007) Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. J Thromb Haemost 5(2):224–231

    Article  PubMed  CAS  Google Scholar 

  15. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S (1993) Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 14(2):205–212

    Article  PubMed  CAS  Google Scholar 

  16. Smith D, Gilbert M, Owen WG (1985) Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66(4):835–839

    PubMed  CAS  Google Scholar 

  17. Vaitkus PT, Barnathan ES (1993) Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 22(4):1004–1009

    Article  PubMed  CAS  Google Scholar 

  18. Heart Failure Society of America (2006) Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12:10–38

    Article  Google Scholar 

  19. Arnold JM, Liu P, Demers C et al (2006) Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 22(1):23–45

    Article  PubMed  Google Scholar 

  20. Srichai MB, Junor C, Rodriguez LL et al (2006) Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J 152(1):75–84

    Article  PubMed  Google Scholar 

  21. Rozmus G, Daubert JP, Huang DT, Rosero S, Hall B, Francis C (2005) Venous thrombosis and stenosis after implantation of pacemakers and defibrillators. J Interv Card Electrophysiol 13(1):9–19

    Article  PubMed  Google Scholar 

  22. Bracke F, Meijer A, Van Gelder B (2003) Venous occlusion of the access vein in patients referred for lead extraction: influence of patient and lead characteristics. Pacing Clin Electrophysiol 26(8):1649–1652

    Article  PubMed  Google Scholar 

  23. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308(6921):81–106

    Article  Google Scholar 

  24. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ (1997) Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 29(5):1074–1080

    Article  PubMed  CAS  Google Scholar 

  25. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 31(2):419–425

    Article  PubMed  CAS  Google Scholar 

  26. Nguyen KN, Aursnes I, Kjekshus J (1997) Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 79(2):115–119

    Article  PubMed  CAS  Google Scholar 

  27. Leor J, Reicher-Reiss H, Goldbourt U et al (1999) Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11, 575 patients with coronary artery disease. J Am Coll Cardiol 33(7):1920–1925

    Article  PubMed  CAS  Google Scholar 

  28. McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV (2006) Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation 113(22):2572–2578

    Article  PubMed  Google Scholar 

  29. Desai A, Healey J, Pfeffer M (2006) Aspirin and the risk of heart failure hospitalization in patients with atrial fibrillation and a prior history of heart failure: an ACTIVE-W analysis. Presented at the 10th annual scientific meeting of the Heart Failure Society of America; September 10–13, 2006

    Google Scholar 

  30. Swedberg K, Cleland J, Dargie H et al (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26(11):1115–1140

    Article  PubMed  Google Scholar 

  31. Hunt SA, Abraham WT, Chin MH et al (2009) Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119(14):e391–479

    Article  PubMed  Google Scholar 

  32. Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323(3):147–152

    Article  PubMed  CAS  Google Scholar 

  33. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation (1994) Stroke prevention in atrial fibrillation II study. Lancet 343(8899):687–691

    Google Scholar 

  34. Antman EM, Anbe DT, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117(2):296–329

    Article  PubMed  Google Scholar 

  35. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 31(4):749–753

    Article  PubMed  CAS  Google Scholar 

  36. de Boer RA, Hillege HL, Tjeerdsma G, Verheugt FW, van Veldhuisen DJ (2005) Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial. Thromb Res 116(4):279–285

    Article  PubMed  Google Scholar 

  37. Echemann M, Alla F, Briancon S et al (2002) Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail 4(5):647–654

    Article  PubMed  CAS  Google Scholar 

  38. Cleland JG, Findlay I, Jafri S et al (2004) The warfarin/aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148(1):157–164

    Article  PubMed  CAS  Google Scholar 

  39. Massie BM, Collins JF, Ammon SE, et al. (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119(12):1616–1624.

    Article  PubMed  Google Scholar 

  40. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK (2006) Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 8(4):428–432

    Article  PubMed  CAS  Google Scholar 

  41. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153(13):1557–1562

    Article  PubMed  Google Scholar 

  42. The Stroke Prevention in Atrial Fibrillation Investigators (1996) Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 156(4):409–416

    Article  Google Scholar 

  43. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. The national consortium of anticoagulation clinics. Ann Intern Med 124(11):970–979

    PubMed  CAS  Google Scholar 

  44. Pullicino P, Thompson JL, Barton B, Levin B, Graham S, Freudenberger RS (2006) Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 12(1):39–46

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA

    Zuheir Abrahams MD, PhD, George Sokos MD & W. H. Wilson Tang MD

Authors
  1. Zuheir Abrahams MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Sokos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. H. Wilson Tang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Western Reserve Heart Care, Corporate Dr. 1335, Hudson, 44236, U.S.A.

    Arman T. Askari

  2. Dept. Cardiovascular Medicine, Cleveland Clinic, Euclid Ave. 9500, Cleveland, 44195, U.S.A.

    A. Michael Lincoff

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Abrahams, Z., Sokos, G., Tang, W.H.W. (2010). Antithrombotic Therapy in Heart Failure and Cardiomyopathy. In: Askari, A., Lincoff, A. (eds) Antithrombotic Drug Therapy in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-235-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-235-3_22

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-234-6

  • Online ISBN: 978-1-60327-235-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation